We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 03, 2019

Bevacizumab as First-Line for Metastatic Breast Cancer

Journal of the National Cancer Institute


Additional Info

Journal of the National Cancer Institute
A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for the Research and Regulatory Enterprises
J. Natl. Cancer Inst 2019 Oct 25;[EPub Ahead of Print], SP Hey, B Gyawali, E D'Andrea, M Kanagaraj, JM Franklin, AS Kesselheim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading